Innovent Initiates First-in-Human Trial of IBI3011, Novel Anti-IL-1RAP Monoclonal Antibody for Gout Treatment
Key Insights
Innovent Biologics (search) has successfully dosed the first participant in a Phase 1 clinical trial of IBI3011 (search), marking the first anti-IL-1RAP (search) monoclonal antibody to enter clinical testing in China.
The single ascending dose study will evaluate safety, tolerability, and pharmacokinetics in 40 healthy volunteers and 24 gout (search) patients, addressing significant unmet medical needs in gout flare treatment.
IBI3011 (search) targets IL-1RAP (search) to simultaneously block multiple IL-1 family inflammatory pathways, potentially offering superior efficacy compared to existing anti-IL-1β therapies.
Innovent Biologics (search) has achieved a significant milestone in gout (search) treatment development by successfully dosing the first participant in a Phase 1 clinical trial of IBI3011 (search), an anti-human Interleukin 1 receptor accessory protein (IL-1RAP (search)) monoclonal antibody. This marks the first anti-IL-1RAP monoclonal antibody to enter clinical testing in China, addressing a substantial unmet medical need in inflammatory disease treatment.
Novel Mechanism Targets Multiple Inflammatory Pathways
IBI3011 (search) represents a breakthrough approach to treating gout (search) flares through its unique targeting mechanism. Unlike existing anti-IL-1β antibodies, IBI3011 targets IL-1RAP (search), a co-receptor that forms complexes with IL-1R1 (search), ST2 (search), and IL-36R (search). This positioning allows the antibody to simultaneously block multiple IL-1 family inflammatory pathways triggered by IL1α (search)/β, IL33 (search), and IL36 (search), respectively.
"Targeting IL-1RAP (search) can simultaneously block several IL-1 family inflammatory pathways, with the potential to rapidly control inflammation, alleviate gout (search) symptoms, and allow earlier initiation of urate-lowering therapy," according to the company's preclinical findings.
Addressing China's Growing Gout Burden
The clinical development of IBI3011 (search) comes at a critical time for China's healthcare system. By 2019, the estimated number of gout (search) patients in China had exceeded 3 million, driven by economic development and rising living standards. When serum uric acid rises above its saturation point, urate crystals deposit in joints, triggering local inflammation and tissue damage that causes gout flares. Recurrent flares can lead to joint destruction and functional impairment, limiting patients' social roles and seriously reducing quality of life.
Current treatment options remain limited and problematic. First-line pharmacologic treatments for gout (search) flares mainly consist of nonsteroidal anti-inflammatory drugs and colchicine, to which certain patients have contraindications or cannot tolerate. Second-line therapies such as glucocorticoids (search) are associated with numerous adverse effects. Only one IL-1β-targeted agent has been approved in China for gout flare treatment, leaving a large unmet need in clinical practice.
Phase 1 Study Design and Objectives
The ongoing Phase 1 trial is designed as a single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 (search) for first-in-human administration. The study plans to enroll a total of 40 healthy volunteers and 24 patients with gout (search) flares, providing comprehensive safety data to support subsequent clinical development.
Preclinical data have demonstrated promising efficacy signals, showing that IBI3011 (search) can significantly suppress gout (search) flares in models of acute gouty arthritis (search). These findings highlight the clinical potential of IBI3011 for treating gout flares and potentially other inflammatory and autoimmune diseases (search).
Strategic Pipeline Integration
IBI3011 (search)'s development is part of Innovent's comprehensive approach to metabolic and autoimmune diseases (search). The company plans to initiate a Phase 3 trial of IBI128 (tigulixostat) in gout (search) patients with hyperuricemia (search), with Phase 2 clinical results presented at APLAR 2025 showing strong efficacy in reducing serum uric acid in patients with gout.
Dr. Lei Qian, Chief R&D Officer of General Biomedicine of Innovent Biologics (search), emphasized the strategic importance of this development: "IB3011 complements the promising Phase 2 clinical results of IBI128 (tigulixostat), which demonstrated excellent efficacy in targeting XOI and is now advancing to Phase 3. By focusing on next-generation global innovations, Innovent is accelerating the development of high-potential molecules and the synergy of these products is expected to bring more innovative therapies that improve the quality of life to patients around the world."
The combination approach offers potential advantages, with IBI3011 (search)'s anti-inflammatory effects complementing tigulixostat's uric acid-lowering properties to provide a more comprehensive treatment strategy for patients with hyperuricemia (search) and gout (search). Additionally, Mazdutide could provide benefits in reducing blood uric acid in the obesity population, creating a portfolio of personalized treatment options.
Broader Therapeutic Potential
Beyond gout (search) treatment, IBI3011 (search)'s mechanism of action positions it for potential applications across multiple autoimmune and inflammatory diseases (search). The IL-1 family cytokines targeted through IL-1RAP (search) are implicated in a broad spectrum of conditions, including acute gouty arthritis (search) and hidradenitis suppurativa (search), suggesting the antibody could address multiple therapeutic areas.
With IBI3011 (search) now entering the clinical stage, Innovent continues to strengthen its pipeline in metabolic and autoimmune diseases (search), reflecting what Dr. Qian described as "a well-structured, echeloned and matrix-like strategy across the fields of cardiovascular and metabolic diseases (CVM), autoimmune diseases, and ophthalmology."